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Abstract 
 
Investment in biotechnology has yielded relatively disappointing results and illustrates the 
gap between the promise and reality of new science. This begs the question: Does research 
on ‘life’ bring different complexities and uncertainties that act as a barrier to the application of 
new biology in global health and agriculture? There has been high quality research on the 
social and ethical impacts of new biology and on the economics of biotechnology, but few 
systematic and integrated attempts to undertake interdisciplinary research and address 
these constraints. This paper provides an original empirical analysis of contemporary and 
future understandings of the bioeconomy using a co-evolutionary and interactive approach to 
examine the extent to which it may be different from other technological transformations. We 
focus on the Innogen Centre’s extensive research results on three important and 
contemporary themes – food and energy security, life science and healthcare translational 
medicine, and global health.
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1 Background and context 
Twenty-first century bioscience and bioeconomy promise solutions to the major global 
challenges of health and agriculture. Influential reports suggest that bioscience and its 
application can meet these global challenges so that biological knowledge becomes crucial 
for a wide range of social and economic transformations (OECD 2009, National Research 
Council 2009). These reports argue that biological advances (in science, technology and 
innovation) will hugely influence social, economic and cultural change. However, the 
benefits of new biology have been promised for a while. Analyses tend to overestimate the 
speed and extent of changes associated with new biology (Hopkins et al 2007, Orsenigo and 
Tait 2008), which begs the question of whether the new biology and the broader bioeconomy 
is just a long time coming or if there are deeper and more fundamental constraints.  
 
In this paper we explore the emergence of new biology through three cases and reveal 
fundamental constraints that are holding back the evolution of the biosciences and their 
applications. We use the term new biology in an inclusive way to mean increasing integration 
of biology, not only molecular biology, with informatics and the social sciences. We use the 
term life science to describe the integration of biological science, technology and innovation 
within the broader bioeconomy. The bioeconomy refers to the set of economic activities 
relating to the invention, development, production and use of biological products and 
processes (OECD, 2009) 
 
We investigate the extent to which new biology is ‘different’ to other areas where science and 
technology influence societal changes. Does biological research, with applications in ‘life’ 
bring different complexities and uncertainties that are slowing applications in health and 
agriculture? We will show the importance of taking a co-evolutionary and interactive 
interdisciplinary approach to analysis of the life sciences (Van der Ven and Garud 1994). 
Rather than a frame that focuses on how major biological advances may influence society, 
economy and culture, we assume that science and social science can co-evolve. We use a 
framework identified in the 1990s and used in the decade from 2002 in the Innogen Centre 
(Wield, 2008). The framework was developed to engage with the increasingly systemic 
integration of, and interactions between: innovation; governance and regulation; and publics 
(Tait, 1990; Wield, 2008).  
 
This framework allows us to analyse the relationships in life sciences. We hypothesise that 
innovation in new biology requires new types of social and institutional arrangements 
between – and within – three main sets of actors that drive  innovation: 
1. The extremely complex group of actors involved in the production of science, technology 
and innovation in research settings, companies,  and new collaborative networks and 
partnerships; 
2. Policy makers and regulators – from narrowly organised regulatory bodies for sub-parts of 
the innovation system, to those responsible for bridging boundaries and proposing regulatory 
innovation; 
3. Citizens and ‘stakeholder’ groups (such as patient interest groups and advocacy 
organisations) who provide an important ‘check’ on the other two sets of stakeholders, for 
example concerning gm crops and drugs advocacy for HIV/AIDS sufferers. 
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This co-evolutionary approach, which recognises the interconnection of different actors and 
events in shaping the current and future possibilities of the biosciences, underpins the framing 
of this paper and the research it draws upon.  Life science research, and associated research 
on the social and economic nature of the life sciences, necessarily requires interdisciplinary 
methods and capabilities. The approach we have developed, including in this paper, provides 
three key insights. First that innovation in the life sciences requires knowledge from multiple 
sources, in a more ‘open’ way, including from users of knowledge, such as patients. Second, 
innovation involves different sources of knowledge interacting with each other in an 
interdisciplinary way such that ideas are shared and combined. Third, these interactions are 
normally specific to a particular context, and each context has its own routines and traditions, 
as we see from the three cases below. 
 
There is evidence that new biology does differ from other sciences. Dupre (1995) has made 
the important observation that science looks disunified as explored through biology. Biology, 
unlike sciences such as physics and chemistry that have historically been favoured in 
philosophies of science, does not look like it has methodological unity or underlying theory 
to link the disparate fields under its domain. There is also evidence that investment in 
application of new biology (biotechnology), has, so far, had disappointing results (Pisano, 
2006). The reasons include that research on biology and the development of biological 
applications have layers of regulation that are stringent and lengthy. Major drug-use disasters 
have led to regulatory regimes that dominate the structure of bio-economic organisations and 
institutions, in universities, research institutes, big pharmaceutical and small biotech 
companies, and health and food institutions. Furthermore, in health in particular, market 
systems are highly structured with weaker direct consumer marketing and large national and 
managed health care systems and policy.  
 
We analyse the changes brought by new biology in three thematic cases: food and energy 
security; translational medicine; and global health. The rationale for these specific thematic 
areas is that they are exemplars of the different ways in which the new biology co-evolves 
with social, economic, industrial and cultural change. They also highlight the crucial 
importance of ‘context’ for the configuration of broader systemic processes. In other words, 
the state of biological knowledge production and application is such that it is transformative 
of health and agriculture but is contingent upon, among other things, the co-evolution of, and 
interaction between, different industries and the resultant products of their R&D; the local 
and global political economy of complex multi-agent knowledge production; and different 
public attitudes to risk and benefit.  The next sections (2-4) focus on the three cases 
introduced above, followed by a conclusions section 5.  
 
2 Food and energy security  
The food and energy case is an exemplar of our theoretical and empirical approach. Its focus 
is the co-evolution of industrial, social and regulatory processes concerning food security and 
sustainable development in developed and developing economies. Food production includes 
the development of new molecular biology, but depends crucially on interdisciplinary 
integration between natural and social scientific knowledge; and between multiple actors, 
including scientists, industry, regulators and policy makers, and various public interest 
coalitions.  
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Agricultural production will face enhanced existing and new pressures in the future. 
Agriculture is presently responsible for feeding seven billion global citizens and estimated to 
rise to 9.5 bn by 2050. In 2009, for the first time, over one billion people were classified as 
food insecure by the UN Food and Agriculture Organisation (FAO, 2009), partially due to 
increased production of crops for biofuels, knock-on changes in land use and commodity 
speculation. Agricultural science involves the slow introduction of new agrichemical 
products, because of the need for tight regulation of food products. The integrated 
introduction of new seeds and chemicals also requires lengthy trials. The time needed for 
agrarian change is dramatically determined by extension and promotion policies. 
Governments have been key to accelerating the process of agrarian change, not least in the 
recent rapid biofuels growth.  
 
Plants are increasingly used as raw materials for new forms of energy production. They have 
been integrated into new energy-focused production systems, such as sugarcane in the 
production of bioethanol or jatropha curca in the production of biodiesel. Plants as a source 
of bioenergy present new challenges for the biosciences: genetic modification may produce 
plants that yield more energy or lead to the development of ‘second generation’ biofuel crops 
that will not impact upon food security, or the promise of cheaper land and labour in parts of 
the global south may undercut the demand for much new R&D (Nuffield, 2011). 
 
Our research evidences that new biology is beginning to impact on food production. 
Companies, organisations and institutions are co-evolving as new biology is incorporated into 
products and processes (Smith, 2010). This is not new. In a previous period of rapid change, 
the green revolution brought new hybrid crop varieties. But results were hugely differentiated 
by geography, crop type, and by the ability of producers to invest in surrounding technical 
and economic infrastructure to promote higher crop yields and systemic change.  Present 
transformation includes step changes in other conditions, such as: increasing corporate 
integration and monopolisation of the food value-chain; the emergence of new configurations 
of food-fuel hybrid value chains and new technologies, including gm crops. 
 
New biology has begun to transform the food and agriculture sectors. Our research shows 
that, at the level of industrial processes, companies previously dominated by chemistry are 
now increasingly drawing on biology and have large interdisciplinary science and business 
teams (Chataway et al, 2004, 2006; Wield et al 2010). Agri-chemical and seeds companies, 
which were previously separate entities with a high degree of independence (the former 
historically more profitable than the latter), are now tightly integrated. New science and 
technology has co-evolved with new actors to bring novel organisational and institutional 
forms, such as large agricultural public-private partnerships integrating researchers, 
industries, donor funders and farmers, to generate new plant breeding techniques useful in 
developing as well as advanced countries (Wield et al, 2010).  
 
More generally, R&D and animal and crop production systems are beginning to respond 
(prompted by incentives, markets and governance systems) to the realisation that climate 
change, global interconnectedness, global energy requirements and new biological 
technologies may bring profound environmental changes in a period of food and energy 
insecurity (Smith, 2010). These challenges are leading to significant public and private sector 
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investments in research, although thoughtful governance of these rapidly evolving global 
systems lags behind investment and incentives to adopt biofuel.  
 
Our results also evidence the important role of food and energy security issues in the framing 
of new biology and how that influences the research agenda (Ayele and Wield, 2005; Wield 
et al, 2010). We have detailed changing public policy and strategic management issues in 
research development and innovation in the most relevant industries (agro-chemicals, seeds, 
farming and retailing) (Chataway et al, 2004, 2006). We have analysed the rapidly changing 
risk regulatory agendas and their role in shaping global innovation networks (Tait 2007; 
2008). We have also revealed the increased collaborative, interdisciplinarity changes in 
knowledge interaction in African public-private partnerships (Ayele et al, 2006), and in 
relationships between the Food and Agricultural Organization of the United Nations and civil 
society organisations in Africa, South Asia and Latin America (Smith and Chataway, 2009).  
 
At the level of national policy we have investigated bioenergy policymaking processes in 
East Africa and South Asia. In Kenya, we co-convened (with the African Centre of 
Technology Studies) a Policy Working Group that brought together all actors to help develop 
the national strategy paper for both biodiesel and bioethanol (www.pisces.or.ke). Given the 
complexity of issues and interactions, driven by both new science and new investment, and 
the range of interested actors - spanning the public sector, the private sector, non-
governmental organisations, and actors from Kenya and well beyond - generating 
appropriate, strategic responses to the promises and risks of biofuels is  important (Smith, 
2010). The approach is now being used in East Africa and in Sri Lanka, drawing heavily on 
our interdisciplinary, participatory approach to the production of new knowledge. 
 
The key issues that emerge from our fieldwork in Europe and Africa are the intensification of 
food production, fibre and energy crop production, the management of natural resource and 
preserve biodiversity, rural economy and increased multi-functionality of land use. But, 
contrary to the dominant food and energy security discourses our research illustrates that 
these issues cannot easily be treated as single elements separated from others, there is no 
single food system. Instead, there are multitudes of fluid, diverse, sensitive and ephemeral 
systems that serve different markets, are based on different agro-ecological conditions and 
are beholden on complex sets of policies, markets and other external stimuli. Empirically, 
rather than focusing on food and energy security, we suggest that an improved approach is to 
focus on understanding the specifics of food insecurity. Each transformation brings new 
organisations and institutions coupled with new knowledge forms, dramatically increasing 
the complexity and inter-disciplinarity of production and consumption systems. 
Understanding these is a prerequisite for building understanding of how to improve security 
of livelihoods. 
 
3 Translational medicine  
Translational medicine (TM) is our second illustrative case study. The concept of TM has 
emerged in clinical, scientific and health policy communities to describe new sets of 
technological and organisational processes needed to better exploit life science innovations 
for healthcare delivery. One key foci has been the need for new collaborative research 
environments and regulatory/policy changes to facilitate innovation of new therapies, which 
despite the promise of life science has not kept pace with increased R&D investment.. TM 
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aims to bridge gaps in the health innovation pathway. The language of ‘bed to bedside and 
back again’ research is a key feature of TM, although its precise definitional status and 
methods of implementation have been quite broad (Butler, 2008; Fitzgerald, 2008). TM 
necessarily requires a co-evolutionary and interactive approach since, as a set of 
interdisciplinary practices it must bring together complex networks of researchers, 
companies, health services and patients if it is to generate innovation. Bringing such groups 
together is happening, but it remains a challenge given the different styles of research (for 
example, wet lab science – in vitro, in vivo, dry informatics – in silico, and epidemiology, and 
social health care research) and different styles of relationships with ‘users’. 
A key driver of TM is the ‘productivity crisis’ and high attrition of new therapeutic 
compounds and the significant and diverse global challenges facing 21
st
 century healthcare 
(Tait & Mittra, 2004; Mittra, 2007, 2008). TM emerged in the mid 1990s as a response to 
concern that despite the wealth of knowledge and expertise on the cellular and physiological 
mechanisms of many debilitating and fatal diseases, few  novel treatments were making it 
through to the clinic. A number of causes were identified.  On the clinical side, there were 
few opportunities for practitioners to bring clinical findings and key insights from the bedside 
to the attention of predominantly lab-based research scientists. On the research side, the 
underlying connections between study results from in vitro, in vivo and in silico studies were 
not being made; and animal models and simulation programs were of insufficient predictive 
value to understand the human condition (Mittra & Milne, 2012) .  
 
Our research has aimed to understand better the new interdisciplinary relationships and the 
extent to which co-evolution of knowledge is occurring.  It shows that scientists, industry and 
regulators are the main drivers of change and change in practices is most striking in the new 
public-private initiatives. Examples include the Translational Medicine Research 
Collaboration (TMRC) in Scotland  and the Center for Translational Molecular Medicine in 
the Netherlands. Scientists and clinicians are embracing TM predominantly to better 
understand and exploit the range of new technologies emerging from the life sciences, and 
enhance the interface between basic science and clinical medicine, whereas industry sees the 
value of TM in its ability to reduce the attrition rate of new drugs and reduce costs of R&D. 
Regulators see the value of TM in its ability to contribute to safer and more effective drugs.   
TM advocates suggest that the key is in the mechanisms to coordinate the disparate activities 
and knowledge domains constitutive of life science innovation, of which TMRC was an 
exemplar.  
 
The TMRC was established in 2006 to develop a world leading network of clinical and 
scientific excellence in Scotland. As a large-scale collaboration between industry, 
government and academia, the initiative received initial funding of £50 million for 5-years of 
research from April 2006-2011. It involved four research strong medical schools; national 
health board; Scotland’s economic development agency Scottish Enterprise, and the 
pharmaceutical firm Wyeth. The idea was to set up a translational initiative beyond the 
preclinical phase. TMRC was an example of a promising collaborative project with a high 
degree of institutional buy-in to tackle translational issues in health innovation. Company 
take-overs led to the loss of the private company But the case study offers lessons and  about 
the institutional infrastructures and organizational relationships needed for TM to fulfill its 
promise of improving healthcare innovation and meet the diverse needs of key stakeholders 
(Mittra, 2012). 
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We have investigated many other relevant reorganisations of R&D within the pharmaceutical 
industry, and the emergence of novel public-private partnerships for health innovation (Mittra 
and Williams, 2007; Orsenigo and Tait, 2008).  For industry, TM has taken on several 
meanings and consequently TM units within major pharmaceutical companies have taken 
different forms. In some, dedicated TM groups have tried to create a more direct connection 
between basic research and patient care, i.e. addressing questions related to how the therapies 
actually work in the clinical setting. For others, the key objective has been to bridge the gap 
from late discovery to early clinical development so that decisions on product candidates can 
be managed on a more evidence-based footing. For others, TM units can serve as conduits for 
accessing external, often experimental, R&D resources either through a consortium of 
research partners or academic collaborations into new public-private partnerships; the idea 
being that sharing resources, skills and expertise, as well as risks associated with drug 
development, can enhance R&D (Mittra & Milne, 2012) Industry believes TM, and the 
interdisciplinary resources and expertise it encourages, will make positive contributions to the 
drug discovery and development processes to R&D costs and timescales (Mittra, 2008).  
 
Major concerns of regulators, (and politicians and the public) are the cost, safety and efficacy 
of new therapeutic products. Pharmaceutical research and product development is subject to 
an extremely high ‘regulatory hurdle’, which is continually changing. New life science 
technologies are helping to identify novel compounds and improve their safety and efficacy 
profiles. Technology is also helping to improve the delivery of compounds to relevant disease 
targets. The integration of basic and clinical knowledge and expertise early in the 
development pathway, through new translational processes, can also be seen as an attempt to 
meet increased regulatory requirements and societal expectations.  
 
As with food and energy then, ‘translation’ presents a number of complex issues, questions 
and opportunities for exploring the future of biomedical innovation in a global context, which 
we have been developing through our research. In this thematic area we have addressed 
issues around the strategic management and sustainability of commercial pharmaceutical 
innovation in the context of new biology and emerging regulatory systems built around it 
(Mittra, 2008); the general framing of regulation, risk and public health policy and their role 
in shaping global innovation networks; and the emergence and exploitation of 
interdisciplinarity in both public and private knowledge production processes.  
 
4 Global Health  
Just as there has been recognition of the need to think about ‘translation’ generally, so there is 
growing recognition that access to new innovations depends not only on excellent basic bio-
science but also on finding new ways to bring together scientists, health professionals and 
social scientists globally to develop and experiment with new mechanisms that may better 
integrate health innovation and health systems.  Our previous research (Chataway et al, 2009, 
2011; Hanlin and Sutz, 2010) has shown the profound gulf between researchers working on 
life science innovation and researchers in other levels of health systems.   
 
This is despite the fact that resources devoted to global health have increased tremendously 
over the past decade (development assistance for health was estimated to have reached 
$26.87 billion by 2010 (IHME, 2010)) as new funders, such as large foundations like the Bill 
and Melinda Gates Foundation, have joined other donors to build huge new health research 
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and innovation institutions and public-private partnerships. These new forms of collaboration 
have brought together a variety of stakeholders not only in the form of private pharmaceutical 
companies with donors, but also non-governmental organisations, patient and consumer 
groups providing the opportunity for a range of voices to be heard throughout the research-
development-access continuum of health innovation.  
 
They have driven traditional actors, such as aid donors and multilateral agencies like the 
WHO and UNICEF, with other stakeholders, to develop new ways to bridge the translational 
medicine gap that is particularly profound in the area of global health. In particular, where 
products are produced for diseases effecting the poorest in society who are unable to pay for 
medicines and often in developing countries where health systems struggle, there is weak 
market incentive for private pharmaceutical companies to invest in drug, vaccine and 
diagnostic development.  In particular, the R&D world associated with these ‘neglected 
diseases’ has become proliferated with what have become known as ‘Product Development 
Partnerships’ (PDPs) which at their height in the late 2000s took over 20% of the total R&D 
funding for neglected diseases. There is also increasing recognition that health impacts, and is 
impacted by, other issues. This includes a strong relationship between agriculture and health 
which is equally mirrored by crossovers in their innovation activities (Hawkes and Ruel, 
2009). Yet, the ways in which health related innovations (particularly diagnostic methods, 
drugs and vaccines) evolve and touch the lives of people will depend on numerous and 
complex ways in which the gaps can be bridged between innovation and health systems but 
also agriculture, finance and education systems. 
 
Our research with colleagues around the world has aimed to bring greater critical analysis and 
understanding of how health systems can be strengthened through the activities of life science 
PDPs.  This builds on the translation theme by asking how specific partnerships can reduce 
global disease burden, especially that affecting the poorest populations in the world. More 
directly, we have asked how innovation can transform access to medicines.   
 
Building on frameworks such as those used in our food and energy research, and on our actor 
interaction framework (Wield 2008), to analyse relationships between innovators, regulators 
and publics; we have built an understanding of how PDPs have been so successful at 
promoting the development of new biology for neglected diseases in global health.  The key 
aspects of this concept are that it recognises, first, the variety of actors involved in making 
innovation activities successful in the life sciences and, second, the value of facilitating 
organisational arrangements (such as coordinating not–for-profits and ensuring frequent 
communication opportunities between scientists working at all stages of the product 
development pipeline) but also institutional mechanisms (especially supportive policy and 
regulatory environments).     
 
Our work has provided empirical evidence of the need for ‘joined up’ interdisciplinary 
thinking between multiple actors from both within and outside science.  In particular, our 
research of PDPs (Chataway and Smith, 2006; Hanlin, 2009; Chataway et al, 2007; Chataway 
et al, 2011) involved in AIDS and malaria vaccine research in Africa and India highlights the 
existence of tensions between different groups involved.  These partnerships were created 
because of the recognition that more joined up thinking was needed to get a vaccine from 
‘bench to bedside’. Coherence was to emerge by bringing together global forms of 
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knowledge of new biology, systems of governance and expertise of markets. Actors were 
assembled from these different worlds into an interdisciplinary assemblage – the product 
development partnership - to develop therapies against neglected diseases. As with TM 
partnerships and food and energy alliances, global health PDPs were developed with the aim 
of bringing together not only all the best scientists involved in neglected disease research but 
also those working in public health, community development, and end users.  
 
Precisely as imagined in our problematisation of the life sciences, progress could only take 
place by building networks both of different types of natural scientist and also social 
scientists, producers and users to co-evolve new technologies of product delivery for 
neglected diseases. We researched various sites for integration in PDPs. We have studied 
clinical trial sites in developed and developing countries where clinical research was taking 
place. We also studied the headquarters of one of the partnerships. We have shown how 
tensions are played out in both types of site (Cacciatori et al, 2010) and have described how 
PDPs have become adept at managing these tensions at a range of scales in order to 
successfully apply bioscience knowledge to real-world problems (Chataway et al, 2007).   
 
This empirical work has brought conceptual thinking on the ways in which collaborations 
between stakeholders involved in global health combine and interact.  We have contributed to 
two specific areas.  First, our empirical work on PDPs has led to a rethinking of the value of 
collaborative efforts in global health.  Specifically, the degree to which having a coordinating 
mechanism is useful to develop the broking and integration of knowledge required in 
interdisciplinary research and action settings in order to involve all stakeholders, not just 
those in the scientific research arena (Chataway et al, 2007; Chataway et al, 2011).  Second, 
we have contributed to thinking about the policy landscape that best promotes 
interdisciplinary activity of this nature.  This research on health innovation systems thinking 
(Chataway et al, 2009) highlights the importance of thinking outside of traditional 
disciplinary boundaries at the policy level and emphasises the importance of including a 
wider range of policy areas in discussions of innovation in order to effectively promote life 
science innovation that reaches the bedsides of the poorest in society.   
 
5 Discussion and Conclusions 
We have investigated how new biology co-evolves with and changes life science economy, 
organisations and institutions (the bioeconomy), in what ways new biology is specific and 
different, and how different contexts matter? We have used a theoretical framing that 
interweaves theories of: the life sciences; innovation, particularly innovation in networks and 
partnerships; and, the complex regulatory regimes within which bioscience and technology 
take place. Our argument bears out that the big issues come from interactions between the 
three main sets of actors: innovators (scientists, technologists, industry); policy makers and 
regulators (including government and the emerging new institutions of governance); and 
public and stakeholder groups.  
 
Our research on life science and innovation networks in food and energy security, 
translational medicine, and global health has been able to throw light on what might be 
constraining life science and also possible improvements. We will summarise how our 
empirical research suggests further ways forward in: 
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1  Social theorisation of new biology and the life sciences, particularly of the 
importance of interdisciplinarity, complexity and context differences; 
2  Social theories of innovation systems, particularly regarding innovation dynamics (in 
single organisations, networks and partnerships) and innovation strategies; and 
3  Social theory of the relationships between, on the one hand, science and innovation, 
and on the other, regulatory regimes and governance systems.  
 
Social science of new biology and the life sciences  
New biology introduces a new degree of objectification to living matter (eg embryos, animal 
integrity). Living things reproduce (as with gene flow from genetically modified organisms - 
gmos) which brings novel implications for risk regulation and intellectual property. The long 
timeframes involved in life science innovation introduce promissory issues and the 
management of expectations (Borup et al, 2006) but we don’t know how to evaluate promises 
which may completely fail but can also overwhelm all other evolutionary paths. Developing 
viable business models is difficult in such circumstances. 
 
Interdisciplinarity in biology is rather well developed, and now includes the bringing together 
of informatics and biology (bioinformatics, systems biology, synthetic biology). By 
comparison, interdisciplinary social study of new biology is less advanced (Barry et al 2008, 
Greaves and Grant 2010, Lyall et al, 2011). Barry et al suggest that interdisciplinary 
collaboration of science with social science is driven by three underlying logics; the logic of 
accountability, where social sciences are expected to enhance accountability of science; logic 
of innovation, making it more linked to users; and logic of ontology, challenging narrow 
understandings of technical objects. The interdisciplinary, highly collaborative practices in 
our study suggest that new configurations are emerging that will prefigure new epistemic 
cultures – communities of practice with language, beliefs and routines. Interdisciplinary 
research that integrates social and natural sciences will be needed to better understand future 
changes. 
 
Social theories of innovation systems 
Innovation is traditionally studied as a firm-based activity, in sectors where firms strive to 
integrate R&D into new products and processes (Freeman and Soete, 1997). Traditionally, 
nations strategise about improving their competitiveness (Porter, 1998). But increasingly, 
innovation has become understood as something that happens within a range of social and 
economic activities, in services, in clusters and networks as well as sectors and regions. The 
life sciences are an exemplar to allow investigation of such approaches to innovation. They 
encompass big pharmaceutical companies – a traditionally high R&D sector which is now 
maturing rapidly, new biotech firms, innovative financing systems, but also a range of 
innovative institutional arrangements such as public-private partnerships for orphan and 
neglected drugs, complex regulation and patient-included research networks (Orsenigo and 
Tait 2008, Mittra and Williams 2007).    
 
Our research on innovation dynamics allows broadening of conceptualisations of innovation 
strategies, including types of policy frameworks, regulatory regimes and global 
configurations such as public-private partnerships for product development of new therapies 
such as vaccines (Chataway and Smith, 2006). This provides insights, first that innovation 
requires knowledge from multiple sources, in a more ‘open’ way, including from users of 
 12 
knowledge. Second, innovation involves different sources of knowledge interacting and co-
evolving. Third, these interactions are normally specific to a particular context, and each 
context has its own routines and traditions.  
 
The relationship between innovation and regulation 
 
Regulation has major influences on innovation processes. Regulation appropriate to one 
policy area and context can have negative impacts in other contexts. Innogen research, 
analysing the relationship between innovators, policymakers and regulators; and citizens, has 
shown that regulatory systems can, by a series of incremental changes over time, become 
increasingly out of step with the regulated area, and also become increasingly complex so 
that a change or addition can have unexpected implications (Tait et al, 2007, Chataway et al 
2006). As a regulatory regime becomes more complex and hierarchical, its practices likely 
become more fragmented. Regulators are in the midst of competing demands from interests, 
values and power of organisations and regulation has become a multi-institution activity that 
can therefore be analysed in a similar way to more open innovation processes and more 
collaborative knowledge systems. The regulatory practices of all groups described above can 
influence the relationship between innovation and regulation.  
 
In conclusion, the emergence and development of bioscience and rapid growth of the 
bioeconomy, as well as the constraints, depend on interactions between three main sets of 
actors , and on the consequent co-evolution of life science, technologies markets, governance 
systems and users. This necessarily depends on the growth not only of new, more open, forms 
of knowledge but on new forms of interdisciplinarity interaction that go beyond a 
straightforward integration of scientific knowledge but on the co-evolution of knowledge 
with the social sciences. The specifics of new biology, detailed in three cases, imply that the 
21
st
 century bioeconomy depends on the development of new interdisciplinary capabilities. 
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